Herantis Pharma Oyj

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. Show More...

  • Website https://www.herantis.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.36 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -1.25 -74.81 -0.67 -3.21 -3.94 0.66 -0.44 -0.85 -1.37 -1.37
    Dividends EUR
    Payout Ratio % *
    Shares Mil 1.0 1.0 3.0 4.0 4.0 5.0 5.0 6.0 7.0
    Book Value Per Share * EUR 6.61 1.99 0.82 -0.09 0.47 0.36 0.24
    Free Cash Flow Per Share * EUR -0.65 -1.78 -1.02 -0.46 -0.7 -0.77
    Return on Assets % -215.82 -27.31 -32.18 -52.01 -73.63 -36.42 -19.88 -44.65 -87.87 -87.87
    Financial Leverage (Average) 22.01 1.36 2.35 6.48 2.83 5.98 5.98
    Return on Equity % -76.52 -115.76 -116.83 -76.41 -208.93 -908.72 -908.72
    Return on Invested Capital % -41.27 -50.29 -77.05 -37.75 -38.76 -57.64 -92.93 -92.93
    Interest Coverage -150.93 -27.2 -26.65 -8.01 -189.45 -52.61 -6.0 -67.93 -8.21 -8.21
    Current Ratio 0.51 0.29 0.06 7.79 9.77 4.72 3.78 1.69 3.61 3.61
    Quick Ratio 0.51 0.29 0.06 7.79 9.77 4.72 3.78 1.69 3.61 3.61
    Debt/Equity 15.42 0.29 1.25 5.09 1.47 3.89 3.89